CytoMed director buys 200,000 shares at $1.50

CytoMed Therapeutics Ltd director and 10% owner Choo Chee Kong purchased 200,000 ordinary shares in July 2026 through two purchases in open market or private transactions at $1.50 per share on July 14 and July 20.

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd director and 10% owner Choo Chee Kong purchased 200,000 ordinary shares in July 2026 through two purchases in open market or private transactions at $1.50 per share on July 14 and July 20.

A Form 4/A amendment corrects the acquisition/disposition indicator to show these as acquisitions, and the Rule 10b5-1 box is unchecked, so the trades are not affirmed as made under a trading plan.

Insider Trade Summary

Net Buyer: 200,000 shares

Net Buy 2 txns

Insider Choo Chee Kong

Role Director, 10% Owner

Bought 200,000 shs ($300K)

Type	Security	Shares	Price	Value
Purchase	ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED F1	100,000	$1.50	$150K
Purchase	ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED F1	100,000	$1.50	$150K

Holdings After Transaction: ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED — 630,324 shares (Direct)

Footnotes (1)

1. F1. This Form 4/A amends the Form 4 originally filed on July 24, 2026 solely to correct the acquisition/disposition indicator in Column 4 of Table I from "D" to "A". No other changes have been made.

Key Figures

Total shares purchased: 200000 shares Purchase price per share: $1.5000 per share Shares purchased on 2026-07-14: 100000 shares +2 more

5 metrics

Total shares purchased 200000 shares Two open-market or private purchases in July 2026

Purchase price per share $1.5000 per share Price for both July 14 and July 20, 2026 transactions

Shares purchased on 2026-07-14 100000 shares Ordinary shares of CytoMed Therapeutics Ltd, direct ownership

Shares purchased on 2026-07-20 100000 shares Ordinary shares of CytoMed Therapeutics Ltd, direct ownership

Number of purchase transactions 2 transactions Reported in the Form 4/A transaction summary as net-buy

Key Terms

Form 4/A, acquisition/disposition indicator, open market or private transaction, ten percent owner, +1 more

5 terms

Form 4/A regulatory

"This Form 4/A amends the Form 4 originally filed on July 24, 2026"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

acquisition/disposition indicator regulatory

"to correct the acquisition/disposition indicator in Column 4 of Table I"

open market or private transaction market

"transaction code description: Purchase in open market or private transaction"

ten percent owner regulatory

"reporting person is_ten_percent_owner: 1, indicating a ten percent owner"

Rule 10b5-1 regulatory

"document-level Rule 10b5-1 checkbox is explicitly unchecked (aff_10b5_one: false)"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchases did GDTC report for Choo Chee Kong in July 2026?

Choo Chee Kong bought 200,000 CytoMed Therapeutics ordinary shares in July 2026. The purchases were split into two 100,000-share transactions on July 14 and July 20 at $1.50 per share, reported as open-market or private acquisitions.

How many CytoMed Therapeutics (GDTC) shares did the director buy in each transaction?

In each transaction, Choo Chee Kong purchased 100,000 ordinary shares of CytoMed Therapeutics Ltd. One buy occurred on July 14, 2026, and the second on July 20, 2026, both reported as direct ownership acquisitions at $1.50 per share.

At what price were the GDTC insider share purchases executed?

Both reported insider purchases were executed at $1.50 per share. Choo Chee Kong acquired 100,000 shares on July 14, 2026 and another 100,000 shares on July 20, 2026 at this same price in open-market or private transactions.

Was the CytoMed Therapeutics (GDTC) insider trading under a Rule 10b5-1 plan?

The transactions are not affirmed as under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is unchecked, indicating these July 2026 purchases were not reported as executed pursuant to a pre-arranged trading plan.

What does the Form 4/A amendment for CytoMed Therapeutics (GDTC) change?

The Form 4/A amendment corrects the acquisition/disposition indicator in Column 4 of Table I from “D” to “A”. It clarifies that the two 100,000-share trades were acquisitions, and explicitly states no other changes were made to the original Form 4.

How many insider purchase transactions did GDTC report in this Form 4/A?

The amendment reports two purchase transactions in CytoMed Therapeutics ordinary shares. Together they total 200,000 shares bought at $1.50 per share, both described as purchases in open market or private transactions and held as direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 09:01 PM Accepted by SEC EDGAR 07/24/2026 - 09:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Choo Chee Kong

(Last) (First) (Middle)

#08-22 ONE COMMONWEALTH, 1

COMMONWEALTH LANE

(Street)

SINGAPORE U0 149544

(City) (State) (Zip)

SINGAPORE

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytoMed Therapeutics Ltd [ GDTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/24/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED	07/14/2026		P		100,000	A(1)	$1.5	530,324	D
ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED	07/20/2026		P		100,000	A(1)	$1.5	630,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4/A amends the Form 4 originally filed on July 24, 2026 solely to correct the acquisition/disposition indicator in Column 4 of Table I from "D" to "A". No other changes have been made.

	/s/ CHOO CHEE KONG	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)